Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Anti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Tsai-Hung, Tseng, Chih-Wei, Wang, Kao-Lun, Fu, Pin-Kuei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708605/
https://www.ncbi.nlm.nih.gov/pubmed/34946303
http://dx.doi.org/10.3390/medicina57121358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708605/
https://www.ncbi.nlm.nih.gov/pubmed/34946303
http://dx.doi.org/10.3390/medicina57121358

Ejemplares similares